IP Library Granted Patent US 11,911,502
Granted Patent B1
US 11,911,502 · App. 17/388,703 · Granted Feb 27, 2024

Pharmaceutical compositions and methods of using the same

Inventors: Jeffrey M. Moshal (Allentown, PA); Michael Libman (Allentown, PA)
Assignee: NODEN PHARMA DESIGNATED ACTIVITY COMPANY
A61K9/0043A61B17/24A61K31/46A61M19/00A61P23/02A61B1/233A61B2017/246
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,911,502
App. No.
17/388,703
Granted
Feb 27, 2024
Kind
B1
Abstract

Novel pharmaceutical compositions including cocaine hydrochloride and methods of treating patients using those pharmaceutical compositions are described.

Claims (15)

1. A method for induction of local anesthesia prior to performing a procedure on, through, or adjacent a mucous membrane of the nasal cavities of a patient comprising:

administering a pharmaceutical composition comprising:

about 3.5% to about 4.0% cocaine hydrochloride, in weight percentages based on total weight of the pharmaceutical composition,

about 0.7 mg/mL to about 1.3 mg/mL sodium benzoate, and

about 1.2 mg/mL to about 1.4 mg/mL citric acid,

provided that the pharmaceutical composition is an aqueous solution,

provided that the pharmaceutical composition has a pH of 2 to 4, and

provided that a concentration of benzoylecgonine in a volume of the pharmaceutical composition is at least 0.1 weight percent and does not exceed about 9.3 weight percent in the volume of the pharmaceutical composition after the volume of the pharmaceutical composition has been stored in a sealed container for six months at a temperature ranging from 38° C. to 42° C. and a relative humidity ranging from 70% to 80%.

2. The method of claim 1 , wherein the procedure comprises nasal endoscopy.

3. The method of claim 1 , wherein the procedure comprises nasal endoscopy with debridement.

4. The method of claim 1 , wherein the procedure comprises laryngoscopy.

5. The method of claim 1 , wherein the pharmaceutical composition comprises:

about 4.0% cocaine hydrochloride, in weight percentage based on total weight of the pharmaceutical composition;

about 1.00 mg/mL sodium benzoate; and

about 1.25 mg/mL citric acid.

Assignments (4)
SECURITY INTEREST Recorded Apr 27, 2026
From: LXO IRELAND DESIGNATED ACTIVITY COMPANY
To: KROLL TRUSTEE SERVICES LIMITED, AS SECURITY AGENT
Reel/Frame 074483/0163 →
CHANGE OF NAME Recorded Dec 10, 2025
From: NODEN PHARMA DESIGNATED ACTIVITY COMPANY
To: LXO IRELAND DESIGNATED ACTIVITY COMPANY
Reel/Frame 073940/0952 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2023
From: GENUS LIFESCIENCES INC.
To: NODEN PHARMA DESIGNATED ACTIVITY COMPANY
Reel/Frame 062999/0559 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2022
From: MOSHAL, JEFFREY M.; LIBMAN, MICHAEL
To: GENUS LIFESCIENCES INC.
Reel/Frame 060071/0309 →
Continuity (4)
Continuation 16510516 · Jul 12, 2019
Continuation 15934562 · Mar 23, 2018
Continuation In Part 15434014 · Feb 15, 2017
Continuation In Part 15427011 · Feb 7, 2017
Cited By (1)
US 12,508,256